Viral Hepatitis
Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein
Article first published online: 7 MAR 2007
DOI: 10.1002/hep.1840360616
Copyright © 2002 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Foo, N.-C., Ahn, B. Y., Ma, X., Hyun, W. and Benedict Yen, T. S. (2002), Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein. Hepatology, 36: 1400–1407. doi: 10.1002/hep.1840360616
Publication History
- Issue published online: 7 MAR 2007
- Article first published online: 7 MAR 2007
- Manuscript Accepted: 26 AUG 2002
- Manuscript Received: 19 JUL 2002
Funded by
- National Institutes of Health. Grant Number: R01CA55578
- National Institutes of Health. Grant Number: P30DK26743
- Abstract
- References
- Cited By
Abstract
Fibrosing cholestatic hepatitis (FCH) is a rapidly progressive form of viral hepatitis B that occurs in severely immunosuppressed patients. Pathologically, the liver in FCH is characterized by widespread hepatocyte vacuolization and apoptosis, which, in contrast to more common forms of hepatitis B, is only rarely associated with significant inflammation. Therefore, it has been proposed that, in FCH, hepatocytes may be injured by a direct cytopathic effect of the virus rather than by the host immune response. In support of this hypothesis, we present evidence that cultured hepatoma cells that had been transfected with a plasmid selectively expressing the viral large surface protein form numerous large vacuoles and undergo apoptosis. The similarity of the cytopathology in FCH in vivo and in these transfected cells in vitro strongly implicates the large surface protein as the direct cause of this acute liver disease. This conclusion is further supported by the published demonstration that hepatocytes tend to accumulate large surface protein in FCH, which may reflect its overexpression by the virus. In conclusion, our data implicate the large surface protein as a major cause of hepatocyte injury in fibrosing cholestatic hepatitis. (HEPATOLOGY2002;36:1400–1407).

1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8)